Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet (ZBH) reported third-quarter 2026 net sales of $2.063 billion, up from the prior-year period, and raised its full-year outlook. Sales rose 3.1% as reported and 3.7% excluding currency effects. Diluted earnings per share fell 13.8% to $1.00; adjusted diluted earnings per share held at $1.90. Net earnings attributable to Zimmer Biomet declined to $191.6 million from $230.9 million.
Knee sales fell 3.1%, while hips rose 6.0%, S.E.T. rose 6.8%, and Technology & Data, Bone Cement and Surgical rose 11.9%. Operating cash flow was $560.0 million, with free cash flow of $372.4 million. The company now expects 2026 reported revenue growth of 4.4%–4.9%, versus 3.9%–4.9% previously, and adjusted diluted earnings per share of $8.50–$8.60, versus $8.47–$8.59. Organic revenue growth excluding currency effects is projected at 3.0%–3.5%, previously 2.25%–3.25%.
Zimmer Biomet (ZBH) plans to preview its vision for intelligent orthopedic surgery at a featured AAHKS symposium on November 6, 2026. The annual meeting runs November 5–8 in the Dallas area.
The company envisions connected systems that support surgeon judgment and link surgical decisions with patient recovery while reducing procedural burden without transferring control. Its symposium will cover personalized surgical planning and execution. Booth displays will include robotics, navigation, knee and hip systems, connected-care tools and perioperative products, alongside medical education sessions.
Zimmer Biomet (ZBH) is the founding sponsor of the Arthritis Foundation's newly announced Comeback Club for people exploring or recovering from joint replacement. The community connects people who have undergone surgery with those considering it to share experiences and learn about life before and after joint replacement. Launch activities are planned at Arthritis Foundation Jingle Bell Run events in November and December.
Zimmer Biomet (ZBH) and THINK Surgical extended their Limited Exclusive Distribution and Supply Agreement for a multi-year period covering the TMINI robotic system. Zimmer Biomet will continue distributing an exclusive version of THINK's wireless, handheld TMINI Miniature Robotic System. This version is compatible with Zimmer Biomet's Persona Knee System.
Zimmer Biomet (ZBH) will webcast its third-quarter 2026 earnings conference call on November 4, 2026, at 8:30 a.m. ET. The quarterly results release will be available that day at 6:30 a.m. ET. The live audio webcast will be accessible through the company's Investor Relations website, with a replay available after the call.
Zimmer Biomet (ZBH) announced several Americas leadership promotions and a restructuring of its commercial organization effective October 1, 2026.
Gary Campbell will become President, Americas, overseeing commercial strategy and execution in the United States, Canada and Latin America and continuing to evolve the U.S. go-to-market model. Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery, expanding his remit to include Global Knees and Hips and leading global portfolio strategy across most of the company’s businesses. Bradley Kessler will become President, Americas – Robotics, Technology and Data, responsible for driving robotics, digital and technology solutions in the Americas and supporting the anticipated 2027 launch of the Monogram next-generation orthopedic robot.
As part of the restructuring, Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company on September 30, 2026. Zimmer Biomet also reiterated its full-year 2026 financial outlook previously provided on August 5, 2026.
Zimmer Biomet (NYSE: ZBH) declared a quarterly cash dividend of $0.24 per share for the third quarter of 2026. The dividend is payable on or about October 30, 2026 to shareholders of record as of the close of business on September 30, 2026.
Zimmer Biomet (NYSE: ZBH) reported second quarter 2026 net sales of $2.177 billion, up 4.8% reported, 4.7% constant currency and 4.0% organic constant currency versus the prior year. Net earnings were $198.3 million, with diluted EPS of $1.03, up 33.8%, and adjusted diluted EPS of $2.07, consistent with last year.
Q2 operating cash flow was $447.9 million and free cash flow $308.3 million. The company raised 2026 reported revenue growth guidance to 3.9%-4.9% and adjusted EPS to $8.47-$8.59, and increased expected 2026 share repurchases to up to $1 billion. Hips, S.E.T. and Technology & Data categories led growth, while Knees were roughly flat. Zimmer Biomet also highlighted FDA 510(k) clearance and first cases of its next-generation ROSA Shoulder System.
Zimmer Biomet (NYSE: ZBH) appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai joins from Alcon, where he held senior international and Asia Pacific leadership roles, following a 22-year career at GE Healthcare in multiple regional positions.
His background spans sales, marketing, services, supply chain, finance and project management across medical devices and related sectors. Desai succeeds Sang Yi, group president of Asia Pacific, who will leave the company on August 28, 2026, after a transition period.
Zimmer Biomet (NYSE: ZBH) will host a webcast and conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026 at 8:30 a.m. ET. A news release with detailed results will be issued at 6:30 a.m. ET the same day. The live audio webcast and replay will be accessible via the company’s Investor Relations website, with U.S./Canada dial-in at (800) 330-6710 and international dial-in at +1 (213) 279-1505, both using conference ID 7090861.